Outcome of Board Meeting

14th August, 2026 Corporate Relationship Department The Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd. Mumbai – 400 001. MUMBAI – 400 051. Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam Sub: Outcome of the Board Meeting held on 14th August, 2026 Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2026 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time (“Listing Regulations”) along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your information. 2. Declared interim dividend of Rs.1.50/- (Rupees One Rupees and paise fifty only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2026-27. The date for taking on record of its shareholders is eligible for the purpose of payment of interim dividend i.e., record date is fixed as Thursday, the day of 20th day of August, 2026. The payment of said interim dividend will start from Wednesday, the day of 26th August, 2026. 3. Evaluating and exploring raising of funds through issuance of equity shares or other securities, including by way of public issue, preferential issue, rights issue, private placement(s), qualified institutions placement(s) and/or any combination thereof or any other method as may be permitted, up to an amount not exceeding ₹2000 Crores (Rupees Two Thousand Crores Only) , in accordance with the applicable provisions of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, (each as amended) and any other applicable law, in such manner, and on such terms and conditions as may be deemed appropriate by the Board in its absolute discretion, subject to the receipt of necessary approvals, including the approval of the members of the Company and such other regulatory and statutory approvals as maybe required. 4. Approved the Notice for the 43rd Annual General Meeting and authorised Sri V. C. Nannapaneni, Chairman and Managing Director for fixing the Date & time of the Annual General Meeting for the Financial Year 2025-2026 through Video Conference (VC) / other Audio Visual Means (OAVM). 5. The Reconstitution of Risk Management Committee and Environment, Social and Governance Committee of the Company w.e.f. 14th August, 2026. The details of the Committee(s) will be available on the website of the Company at https://www.natcopharma.co.in/investor-relations/policies A Copy of Press release is also enclosed for your information. Meeting commenced at 12.15 p.m. and concluded at 14.00 p.m. Thanking you Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: as above Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd NATCO House Road No.2, Banjara Hills Hyderabad-500 034, India Hyderabad, India, August 14th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for first quarter of financial year 2027. NATCO records ₹794.4 Crore consolidated revenue and ₹206.5 Crore of profit after tax for Q1 FY27 • NATCO recorded consolidated total revenue of INR 794.4 Crore for the quarter ended on 30th June 2026, as against INR 1,390.6 Crore for the corresponding quarter last year. Decline is largely attributable to lower Lenalidomide revenue in the current quarter which was partially offset by growth in the base business. The net profit for the period, on a consolidated basis, was INR 206.5 Crore, as against INR 480.3 Crore for the corresponding quarter last year. • For the quarter, revenue of the associate company, Adcock Ingram Holdings Limited, South Africa was at INR 1,582.8 crores and profit after tax was at INR 242.2 crores. NATCO's share of profit based on the holding as on 30th June 2026 of 35.75% stood at INR 84.3 crores. In July 2026, NATCO acquired additional 13.25% stake in Adcock Ingram Holding Limited taking the total holdings to 49%. • The Board of Directors have declared an interim dividend of INR 1.5 per equity share of INR 2 each during Q1FY27. Segmental Revenue Split (INR Crore) Business Segments Q1FY27 Q1FY26 Active Pharmaceutical Ingredients (API) 66.7 52.6 Domestic Pharmaceutical Formulations 136.4 107.0 International Formulations (Incl. profit share and subsidiaries) 477.1 1,120.9 Crop Health Sciences (CHS) 40.8 34.7 Other operating and non-operating income 73.4 75.4 Total 794.4 1,390.6 Natco Pharma Limited Regd. Off. NATCO Pharma Ltd NATCO House Road No.2, Banjara Hills Hyderabad-500 034, India About NATCO Pharma Limited NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company’s different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter). Earnings Call Details: • Date: 14th August 2026, Friday • Time: 5.30 PM IST • Dial-in-Numbers: • India: (+91 22) 62801222 / 71158123 • US: 18667462133 • UK: 08081011573 • Singapore: 8001012045 • Diamond pass link: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8730033&linkSecurity String=43c052c9f4 For further information please contact: Rajeev Menon - Investor Relations ir@natcopharma.co.in/r.menon@natcopharma.co.in